

## Special Issue

# Role of Immunotherapy in Gastroesophageal Cancers: Advances, Challenges and Future Strategies

### Message from the Guest Editor

In recent years, the use of immunotherapy has led to significant advances in the gastroesophageal cancers treatment landscape with pivotal trials establishing PD-1 blockade as a new standard of care for selected patients, in both respectable and first-line metastatic settings. However, the survival outcomes for the advanced disease are still humbling due to the non-inflamed nature of these tumors, necessitating the development of combinatorial approaches to overcome the resistance to immunotherapy. The aim of our Special Issue is to provide a platform for original research and review articles focused on therapeutic approaches being developed for gastroesophageal cancers to improve the prognosis and survival rates of patients treated with immunotherapies, while addressing the challenges associated with an acquired resistance. Dr. Ali H. Zaidi

---

### Guest Editor

Dr. Ali Zaidi

Esophageal and Lung Institute, Allegheny Health Network Institute, Pittsburgh, PA 15212, USA

---

### Deadline for manuscript submissions

closed (15 August 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/159879](https://mdpi.com/si/159879)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)